NOVARTIS-CENA713B2311

Study Sponsor: Novartis

Study Title

A 24-week Prospective, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy, Tolerability, and Safety of 3-12 mg/day of Rivastigmine Capsules in Patients with Parkinson’s Disease Dementia

Medicine or Vaccine (generic name)

rivastigmine

Sponsor Identification Number

CENA713B2311

Trial Registry Identification Number(#'s)

Not available

Medical Condition

Parkinson's Disease Dementia

Phase

Phase 3

Link to study details on the Novartis Clinical Study Register

https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=1616

Link to study details on ClinicalTrials.gov (if available)

Not available

Link to study details on EudraCT (if available)

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

Date Added to this Site

July 2016